A Clinical Pilot Study of Newly Developed Ostomy Tapes and How They Adhere to the Skin

Not Applicable

Completed

• Conditions: Stoma Site Leakage
• Interventions: Device: Test product A; Device: Test product B; Device: Comparator

• Registration Number: NCT04544566
• Lead Sponsor: Coloplast A/S

Brief Summary

An investigation of non-CE marked stoma tape products. This investigation is a randomised, open-label, comparative, cross-over study, with three test periods. In total, 12 subjects will be included and randomised.

Detailed Description

The test products are non-CE marked stoma tape products. This investigation is a randomised, open-label, comparative, cross-over study, with three test periods. In total, 12 subjects will be included and randomised.

Study Timeline

• Study First Submitted: 2020-06-26
• Study Start: 2020-07-07
• Primary Completion: 2020-08-21
• Study Completion: 2020-08-21
• Study First Submitted QC: 2020-09-03
• Study First Posted: 2020-09-10
• Results First Submitted: 2020-12-11
• Status Verified: 2021-04
• Results First Submitted QC: 2021-04-13
• Last Update Submitted: 2021-04-13
• Results First Posted: 2021-05-06
• Last Update Posted: 2021-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Has given written informed consent
• Be at least 18 years of age and have full legal capacity
• Have had a stoma for more than ½ year
• Have intact skin on the area used in the study (Assessed by investigator, see Appendix 1).
• Willing to change baseplate every second day or less frequent
• Willing to avoid using Concave baseplate during the study.
• Willing to avoid the use of barrier creams or similar that affect the skin/adhesive interface under the tape.

Exclusion Criteria

• Currently receiving or have within the past 2 months received radio-and/or chemotherapy
• Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet(injection) treatment
• Is pregnant or breastfeeding
• Having dermatological problems in the peristomal area (assessed by investigator)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Comparator	Test product B	The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
Comparator	Comparator	The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
Test product B new adhesion material	Test product B	The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
Test product A new adhesive material	Test product A	The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
Test product B new adhesion material	Comparator	The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
Comparator	Test product A	The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
Test product A new adhesive material	Test product B	The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
Test product A new adhesive material	Comparator	The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
Test product B new adhesion material	Test product A	The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.

Primary Outcome Measures

Name	Time	Method
Mean Adherent Area Measured by Photo of Used Tape	Tapestrips per test product were removed from the baseplate at each product change and saved for the next site visit every 7-9 days for evaluation	The adherent area (cm2) measured per baseplate change after use shows how effectively the ostomy tape adheres to the skin. After removal of the ostomy tape, a photo of the tape was taken. The adherent area was measured from the photo and an image analysing program.

Secondary Outcome Measures

Name	Time	Method
Erythema Measured After Tape Removal by Photos	The measurements were carried out after 7-9 days of treatment with the test tape	A change in the surface skin colour is known to be related to a change in the blood flow. This can be measured non-invasively with a spectrophotometric instrument (Derma-spectrophotometer, Cortex Technology A/S, Hadsund) where both the redness and the colour of the skin are measured. Furthermore, visual assessments of photos have been used in several exploratory clinical investigations by Coloplast A/S to explore how adhesives affect the skin. The visual assessment is conducted by trained personnel and is a valuable tool for assessing newly developed adhesives and their impact on skin in the early development phases.
Erythema Measured After Each Treatment Period by Spectrophotometric Method	The measurements were carried out after 7-9 days of treatment with the test tape	A change in the surface skin colour is known to be related to a change in the blood flow. This can be measured non-invasively with a spectrophotometric instrument (Derma-spectrophotometer, Cortex Technology A/S, Hadsund) where redness of the skin is measured. The measurement of erythema is based on an active color detecting chip. Illumination is provided by two high intensity white LEDs. The spectrophotometer accommodates the color sensor, filters, optics and light source. Light is provided by two high intensity with LEDs and a unique feature is the guiding light, which illuminates the target during the positioning of the device. The LEDs illuminates the target area and the skin color measurement is performed. The measurements performed with the spectrophotometric instrument do not have units. But the measures are used for the estimation of the level of the redness (hemoglobin) in the skin. The higher the value, the more pigment in the skin.
Feeling of Security	The evaluation was carried out after 7-9 days of treatment with the test tape	Subjects will be asked how they rate feeling of security ("How was the feeling of security?) on a five point scale, when wearing the tape; 1. Very Poor, 2. Poor, 3. Acceptable, 4. Good, 5. Very Good.
Comfort	The evaluation was carried out after 7-9 days of treatment with the test tape	Subjects will be asked how they perceived the comfort of the tape ("How comfortable was the tape to wear?") and rate comfort on a 5-pont scale; 1. very discomfortable, 2. Discomfortable, 3. Acceptable, 4. Comfortable, 5. Very comfortable.
Skin Issues in the Area Covered by the Tape	The evaluation was carried out after 7-9 days of treatment with the test tape	Subjects will be asked if they had any skin-related complications in the area covered by the tape (yes, no).
Adverse Events	27 days	All Adverse Events are captured and documented throughout the study.
Adhesion of Tape	The evaluation was carried out after 7-9 days of treatment with the test tape	Subjects will be asked how they perceive the immediate adhesion to the skin ("how was the immediate adhesion to the skin?) and rate adhesion on a five-point scale: 1. Very poor, 2. Poor, 3. Acceptable, 4. Good, 5. Very good.

Trial Locations

Locations (1)

Bispebjerg hospital; 🇩🇰 Copenhagen, Copenhagen NV, Denmark